Comparative Pharmacology
Head-to-head clinical analysis: PARAPLATIN versus ZYTIGA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PARAPLATIN versus ZYTIGA.
PARAPLATIN vs ZYTIGA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Carboplatin, a platinum-based alkylating agent, forms interstrand and intrastrand DNA cross-links by binding to DNA guanine bases, inhibiting DNA replication and transcription, leading to cell cycle arrest and apoptosis.
Abiraterone acetate is converted in vivo to abiraterone, an androgen biosynthesis inhibitor that selectively inhibits the enzyme CYP17 (17α-hydroxylase/C17,20-lyase). This inhibition blocks androgen production in the testes, adrenal glands, and prostate tumor tissue.
360 mg/m2 IV every 3 weeks or area under the curve (AUC) 4-6 mg/mL/min IV every 3-4 weeks using Calvert formula.
1000 mg orally once daily on an empty stomach, at least 1 hour before or 2 hours after a meal, in combination with prednisone 5 mg orally twice daily.
None Documented
None Documented
Terminal elimination half-life: 2.6-5.1 hours (initial phase), 22-52 hours (terminal phase) for total platinum; 1.3-2.1 hours for ultrafilterable platinum. Clinically, the terminal half-life reflects slow release of protein-bound platinum.
The terminal elimination half-life of abiraterone is approximately 12 hours (range 9–18 hours) following oral administration, supporting twice-daily dosing.
Renal excretion: ~70-90% of platinum is excreted in urine within 24 hours, primarily as unchanged drug. Fecal excretion: <6%. Biliary excretion: minimal.
Abiraterone is primarily eliminated via hepatic metabolism with less than 1% excreted unchanged in urine. Approximately 88% of a radiolabeled dose is recovered in feces (mainly as metabolites) and about 5% in urine.
Category C
Category C
Antineoplastic Agent
Antineoplastic Agent